Want to see IN:AKUMS full AI Analyst Report?
Top Page
Akums Drugs and Pharmaceuticals Limited
(AKUMS)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹751.00
▲(9.73% Upside)
Action:Downgraded
Date:09/11/26
The score is driven primarily by improved fundamentals—stronger balance sheet, profitable turnaround, and robust recent cash generation—tempered by margin/earnings volatility. Technicals are moderately supportive given the longer-term uptrend but show mixed near-term momentum. Valuation is the main constraint due to the high P/E and low dividend yield.
Positive Factors
Revenue Growth
Rising revenue indicates expanding commercial activity for Akums’ formulation manufacturing business and supports better utilization of its operating base. Continued top-line growth can strengthen customer relationships, improve scale economics, and provide a foundation for rebuilding sustainable earnings over the next several quarters.
Negative Factors
Margin Compression
The sharp FY26 margin decline indicates that revenue growth has not translated consistently into profitability, whether from cost pressure, product mix, or other factors cited in the pack. Persistent compression would weaken operating leverage, reduce reinvestment capacity, and make earnings less durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Rising revenue indicates expanding commercial activity for Akums’ formulation manufacturing business and supports better utilization of its operating base. Continued top-line growth can strengthen customer relationships, improve scale economics, and provide a foundation for rebuilding sustainable earnings over the next several quarters.
Read all positive factors
Akums Drugs and Pharmaceuticals Limited (AKUMS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹107.91B
Dividend Yield0.44%
Average Volume (3M)8.89K
Price to Earnings (P/E)36.0
Beta (1Y)1.22
Revenue Growth9.18%
EPS Growth-14.57%
CountryIN
Employees7,337
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume7,588
30 Day Avg. Volume8,889
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.23
Revenue Forecast (FY)₹50.25B
Akums Drugs and Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (AP...
How the Company Makes Money
AKUMS primarily makes money by providing contract manufacturing and related development services to pharmaceutical and healthcare brand owners. Its core revenue stream is the sale of finished pharmaceutical formulations manufactured on behalf of c...
Akums Drugs and Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
86
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.26B | 43.59B | 40.71B | 40.20B | 34.75B | 36.47B |
| Gross Profit | 7.62B | 9.37B | 16.05B | 14.37B | 11.67B | 12.69B |
| EBITDA | 2.39B | 6.31B | 5.29B | 1.31B | 3.09B | -821.80M |
| Net Income | 1.88B | 2.55B | 3.38B | -40.35M | 948.55M | -2.53B |
Balance Sheet | ||||||
| Total Assets | 51.59B | 54.47B | 41.13B | 35.16B | 32.67B | 30.69B |
| Cash, Cash Equivalents and Short-Term Investments | 16.78B | 16.81B | 5.82B | 2.88B | 1.50B | 1.03B |
| Total Debt | 902.87M | 1.57B | 882.12M | 5.65B | 6.19B | 3.95B |
| Total Liabilities | 19.91B | 21.16B | 10.50B | 27.96B | 25.43B | 24.44B |
| Stockholders Equity | 31.49B | 33.13B | 30.47B | 7.09B | 7.17B | 6.22B |
Cash Flow | ||||||
| Free Cash Flow | 13.13B | 9.80B | 1.93B | 1.87B | -1.52B | -2.26B |
| Operating Cash Flow | 15.47B | 12.11B | 4.65B | 4.98B | 1.77B | 318.54M |
| Investing Cash Flow | -12.71B | -9.69B | -5.48B | -3.30B | -3.05B | -2.35B |
| Financing Cash Flow | -5.29B | 430.11M | 727.88M | -1.08B | 1.25B | 2.36B |
Akums Drugs and Pharmaceuticals Limited Technical Analysis
Negative
684.40
Price Trends
765.59
Negative
704.81
Negative
595.76
Positive
Market Momentum
-24.92
Positive
33.56
Neutral
9.03
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AKUMS, the sentiment is Negative. The current price of 684.4 is below the 20-day moving average (MA) of 762.50, below the 50-day MA of 765.59, and above the 200-day MA of 595.76, indicating a neutral trend. The MACD of -24.92 indicates Positive momentum. The RSI at 33.56 is Neutral, neither overbought nor oversold. The STOCH value of 9.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AKUMS.
Akums Drugs and Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹154.96B | 25.69 | ― | 0.40% | 7.93% | 21.51% | |
69 Neutral | ₹107.91B | 36.04 | ― | 0.44% | 9.18% | -14.57% | |
67 Neutral | ₹95.08B | 15.52 | ― | 0.48% | 7.28% | 68.82% | |
63 Neutral | ₹176.18B | 59.26 | ― | 0.12% | 27.91% | 167.68% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹149.44B | 42.13 | ― | 0.53% | 16.27% | -23.50% |
* General Sector Average
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
718.35
263.50
57.93%
IN:ALIVUS
Glenmark Life Sciences Limited
1,343.45
440.43
48.77%
IN:JUBLPHARMA
Jubilant Pharmova Limited
955.75
-158.28
-14.21%
IN:SHILPAMED
Shilpa Medicare Limited
903.05
542.88
150.73%
IN:STAR
Strides Pharma Science Ltd
1,093.20
283.44
35.00%
IN:SUDEEPPHRM
Sudeep Pharma Limited
1,021.90
249.56
32.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.